News coverage about Baxter International (NYSE:BAX) has trended somewhat positive recently, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Baxter International earned a news impact score of 0.16 on Accern’s scale. Accern also gave news headlines about the medical instruments supplier an impact score of 46.7286623156269 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK (zacks.com)
- Global Hemostats Market Growth Forecast by 2023: Baxter International Inc., Inc., Pfizer, Inc. and Ethicon – The Financial (thefinancialconsulting.com)
- Baxter International Inc. (BAX) Stock price down move to its 20 SMA, receiving consideration form Day Traders – Analyst Recommendation (press release) (blog) (analystrecommendation.com)
- Here's Why You Should Invest in Baxter International Now (finance.yahoo.com)
- Baxter completes acquisition of RECOTHROM and PREVELEAK (dotmed.com)
Baxter International stock traded up $0.09 during trading hours on Thursday, hitting $66.55. 2,103,645 shares of the stock traded hands, compared to its average volume of 3,293,855. The company has a market cap of $36,140.69, a price-to-earnings ratio of 51.55, a P/E/G ratio of 1.93 and a beta of 0.82. The company has a quick ratio of 2.05, a current ratio of 2.57 and a debt-to-equity ratio of 0.38. Baxter International has a 12 month low of $51.39 and a 12 month high of $72.58.
The business also recently declared a quarterly dividend, which will be paid on Monday, April 2nd. Investors of record on Friday, March 2nd will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend is Thursday, March 1st. Baxter International’s dividend payout ratio (DPR) is currently 49.61%.
Baxter International declared that its Board of Directors has authorized a share buyback program on Tuesday, February 20th that authorizes the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.
Several research firms recently commented on BAX. Evercore ISI began coverage on shares of Baxter International in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $71.00 target price on the stock. Bank of America upgraded shares of Baxter International from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Raymond James Financial upgraded shares of Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 target price on the stock in a research report on Wednesday, January 3rd. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “buy” rating and set a $76.00 target price on the stock in a research report on Monday. Finally, JPMorgan Chase & Co. upgraded shares of Baxter International from a “neutral” rating to an “overweight” rating in a research report on Tuesday, January 2nd. Seven analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $71.27.
In other Baxter International news, Director Carole J. Shapazian sold 4,990 shares of the company’s stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $66.05, for a total transaction of $329,589.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Giuseppe Accogli sold 28,641 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $67.00, for a total transaction of $1,918,947.00. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by insiders.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.